Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide + dexamethasone for newly diagnosed primary plasma cell leukemia
NL-OMON25322Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib, lenalidomide and dexamethasone in plasma cell leukaemia (PCL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Aug 2015; status: recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NL-OMON25322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25322.